Alpine Global Management, LLC Seagen Inc. Transaction History

Alpine Global Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 21, 2023	BUY	$191.51 - $216.16 $3.54 Million - $4 Million	18,500 Added 92.5%	38,500 $8.17 Million
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $3.54 Million - $4 Million	18,500 Added 92.5%	38,500 $8.17 Million
Q2 2023 Nov 21, 2023	BUY	$187.64 - $206.25 $2.54 Million - $2.79 Million	13,550 Added 210.08%	20,000 $3.85 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $2.54 Million - $2.79 Million	13,550 Added 210.08%	20,000 $3.85 Million
Q1 2023 Nov 21, 2023	SELL	$127.59 - $203.08 $4.09 Million - $6.51 Million	-32,050 Reduced 83.25%	6,450 $1.31 Million

Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $822,955 - $1.31 Million	6,450 New	6,450 $1.31 Million
Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $499,132 - $658,708	-4,173 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $594,944 - $796,458	4,173 New	4,173 $645,000
Q1 2021 May 13, 2021	SELL	$137.51 - $190.8 $272,407 - $377,974	-1,981 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $326,132 - $419,833	1,981 New	1,981 $347,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Alpine Global Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpine Global Management, LLC with notifications on news.